Tao et al. demonstrated that the anticancer effects of xanthatin on NSCLC require the interruption of GSK-3β activity in conjunction with the preferential inhibition of constitutive STAT3 activation [138]. Here, GSK3B is linked to non-small cell lung carcinoma.